Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribosomal protein S29 pseudogene 19 (RPS29P19) is classified as a processed pseudogene in the human genome. It originates from the RPS29 gene, which encodes a structural component of the 40S subunit of ribosomes involved in protein synthesis. As a pseudogene, RPS29P19 does not produce a functional protein product and is not known to play a direct biological role or be involved in therapeutic targeting. The presence of such pseudogenes in the genome is a reflection of evolutionary duplications and retrotranspositions of functional ribosomal protein genes, but these copies typically lack the regulatory elements or intact coding sequences necessary for expression. There is no evidence suggesting pseudogenes like RPS29P19 are implicated in human disease, serve as biomarkers, have drug interactions, or present any specific safety concerns. RPS29P19 is not a therapeutic target and is not a misnamed receptor or enzyme; it is a non-functional genomic sequence derived from the RPS29 functional gene. If you intended to refer to the functional ribosomal protein, use "Ribosomal protein S29" or "RPS29".
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein S29 pseudogene 19 (RPS29P19).